11:10 AM EDT, 05/02/2025 (MT Newswires) -- Eli Lilly ( LLY ) benefits from "lots of untapped volume to capture" in the obesity drug market ever after Zepbound's exclusion from CVS Health's ( CVS ) preferred list, Deutsche Bank said Friday in a note.

"Commercialization of the chronic obesity opportunity is still in early innings" after Lilly's Zepbound launched in December 2023 and Novo Nordisk's ( NVO ) Wegovy debuted in June 2021, the report said.

Customers are likely opting for Zepbound after trials demonstrating a 20% weight loss advantage versus Wegovy at 14% after 72 weeks, Deutsche Bank said.

Zepbound's cash-pay vial at $349 to $499 a month is "virtually on par with Wegovy's new to brand scripts," the report said.

Deutsche Bank reiterated its buy rating on Lilly stock with a 12-month target price of $1,010.

Lilly shares rose 2.9% in recent Friday trading, and Novo Nordisk ( NVO ) jumped 5.3%.

Price: 816.97, Change: +22.87, Percent Change: +2.88